As of Oct 20
| +1.22 / +2.41%|
The 16 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 65.00, with a high estimate of 101.00 and a low estimate of 46.00. The median estimate represents a +25.14% increase from the last price of 51.94.
The current consensus among 17 polled investment analysts is to Buy stock in Sarepta Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.